Evaluation of the Comparative Safety and Efficacy of Artemisinin-Piperaquine and Artemether-Lumefantrine for the treatment of acute uncomplicated Malaria among Children in Ibadan, South-West Nigeria.

Abstrakt

Background- Artemisinin-based-combination

therapies (ACT), are the drugs of choice in the

treatment of malaria globally because of their good

tolerability and efficacy. Although Artemether

lumefantrine (AL) and Artesunate-amodiaquine are

the ACTs of choice in Nigeria, there are other ACTs

in the market of which artemisinin-piperaquine (AP)

is one. There is paucity of information about the

safety and efficacy of AP in Nigeria. In this study,

we evaluated the safety and efficacy of AP against

AL, the preferred ACT in Nigeria.

Methods- Children (114) aged 2-10 years with acute

uncomplicated malaria were enrolled and followed

up using the WHO antimalarial efficacy testing

protocol. Enrollees were randomized to receive AP

(56) or AL (58) at standard doses for three days.

Laboratory evaluations for hematological, liver and

renal functions were done at D0, D7 (and D28 if

necessary) as part of safety evaluation.

Results - Geometric mean parasite densities were

17,406/µL and 11,571/µL for AP and AL treated

children respectively. Response of infection to

treatment was prompt. Uncorrected adequate clinical

and parasitological response (ACPR) rate for AP was

96.1% and for 90.4% AL. while polymerase chain

reaction (PCR) corrected ACPR was 100% for both.

Parasite clearance time was significantly shorter for

AL (1.81±0.63 days) versus 2.34±0.70 days for AP

(ρ <0.001). Fever clearance times were 1.13±0.34

and 1.33±0.66 days (ρ=0.181) for AP and AL

respectively. Gametocyte clearance time was shorter

for AL than AP (3 versus 7 days). Both drugs were

well tolerated.

Conclusion- AP and AL was found to be safe and

efficacious for the treatment of uncomplicated

malaria in children in the study area.

PDF (angielski)

Bibliografia

World Health Organization. Guidelines for the

treatment of malaria. Third edition. Geneva

http://www.who.int/malaria/publications/

atoz/9789241549127/en/

World Health Organization. Factsheet on the

World Malaria Report 2013.Geneva 2013. http:/

/ w w w . w h o . i n t / m a l a r i a / m e d i a /

world_malaria_report_2013/en/

World Malaria Report 2016. Geneva: World

Health Organization; 2016. Licence:CC BYNC-SA 3.0 IGO.

Malaria Consortium. Artemisinin-based

Combination Therapy (ACT) [Internet]. 2016

Available from: http://www.malaria

consortium.org/pages/112.htm

Federal Ministry of Health (FMOH). National

antimalarial treatment policy. National Malaria

and Vector Control Division Abuja-Nigeria.

Jianping S, Socheat D, Suon Seila BT, et al.

Randomized trials of artemisinin-piperaquine,

dihydroartemisinin-piperaquine phosphate and

artemether-lumefantrine for the treatment of

multi-drug resistant falciparum malaria in

Cambodia-Thailand border area. Malar J. 2011

Aug 10; 10:231. http://dx.doi.org/10.1186/1475-

-10-231

Xuan TN, Trung TN, Phong NC, et al. The

efficacy and tolerability of artemisininpiperaquine (Artequick®) versus artesunateamodiaquine (CoarsucamTM) for the

treatment of uncomplicated Plasmodium

falciparum malaria in south-central Vietnam.

Malar J. 2012 Jun 28; 11:217. https://doi.org/

1186/1475-2875-11-217

National Bureau of Statistics, Nigeria.

Population (states). 2006. [Internet]. Available

from:http://www.population.gov.ng/images/

Vol%2003%20Table%20DSx%20LGAPop%20

by%20SDistrict-PDF.pdf

Blackwelder WC. “Proving the null hypothesis”

in clinical trials. Control Clin Trials. 1982

Dec; 3(4):345–353.

World Health Organization. Basic malaria

microscopy –Learner’s guide. 2nd edition.

Feb. ISBN: 9241547820. http://

www.who.int/malaria/publications/atoz/

/en/

Trung TN, Tan B, Phuc DVand Song J. A

randomized, controlled trial of artemisininpiperaquine vs dihydroartemisinin-piperaquine

phosphate in treatment of falciparum malaria.

Chin J Integr Med. 2009 Jun 1; 15(3):189–92.

https://link.springer.com/article/10.1007/

s11655-009-0189-6

Falade C and Manyando C. Safety profile of

Coartem®: the evidence base. Malar J. 2009;

(1):1–14. http://dx.doi.org/10.1186/1475-

-8-S1-S6

Falade CO, Ogundele SO, Yusuf SM, Ladipo

SM and Ademowo OG. High Efficacy of Two

Artemisinin Based Combinations (ArtemetherLumefantrine and Artesunate Plus

Amodiaquine) For Acute Uncomplicated

Malaria in Ibadan, Nigeria. Tropical Medicine

& International Health , 2008; 13 (5): 635 -

http://onlinelibrary.wiley.com/doi/10.1111/

j.1365-3156.2008.02043.x/abstract

Makanga M, Bassat Q, Falade C. O, et al.

Efficacy and safety of artemetherlumefantrine in the treatment of acute,

uncomplicated falciparum malaria: a pooled

analysis. American Journal of Tropical

Medicine and Hygiene; 2011; 85(5):793-804.

http://www.ncbi.nlm.nih.gov/pmc/articles/

PMC3205621/

WWARN Parasite Clearance Study Group.

Baseline data of parasite clearance in patients

with falciparum malaria treated with an

artemisinin derivative: an individual patient data

meta analysis. Group Malar J (2015) 14:359.

DOI 10.1186/s12936-015-0874-1.

White NJ (2018). Anaemia and malaria.

malaria Journal. 17:371 https://doi.org/

1186/s12936-018-2509-9, 2018

Bousema T and Drakeley C. Epidemiology

and Infectivity of Plasmodium falciparum and

Plasmodium vivax Gametocytes in Relation to

Malaria Control and Elimination. Clin

Microbiol Rev. 2011 Apr 1; 24(2):377–410.

http://cmr.asm.org/content/24/2/377.

Price RN, Simpson JA, Nosten F, et al. Factors

contributing to anemia after uncomplicated

falciparum malaria. Am J Trop Med Hyg.2001

Nov; 65(5):614–22. https://www.ncbi.nlm.nih.

gov/pmc/articles/PMC4337986/

Aitken EH, Alemu A and Rogerson SJ.

Neutrophils and Malaria. Front Immunol

[Internet]. 2018 [cited 2019 Jan 7]; 9. Available

from: https://www.frontiersin.org/articles/

3389/fimmu.2018.03005/full

Cairns ME, Walker PGT, Okell LC, et al.

Seasonality in malaria transmission:

Implications for case-management with longacting artemisinin combination therapy in sub-

AP and AL antimalarial efficacy and safety in Southwest Nigeria 95

Saharan Africa. Malar J. 2015; 14(321). https:/

/doi.org/10.1186/s12936-015-0839-4.

Sowunmi A, Ntadom G, Akano K, et al.

Declining responsiveness of childhood

Plasmodium falciparum infections to

artemisinin-based combination treatments ten

years following deployment as first-line

antimalarials in Nigeria. Infect Dis Poverty.

Aug 6;8(1):69.

WWARN Gametocyte Study Group.

Gametocyte carriage in uncomplicated

Plasmodium falciparum malaria following

treatment with artemisinin combination therapy:

a systematic review and meta-analysis of

individual patient data, WWARN Gametocyte

Study Group BMC Medicine (2016) 14:79. DOI

1186/s12916-016-0621-7